Fact based stock research
Qiagen (NYSE:QGEN)


Qiagen stock research in summary

qiagen.com


Qiagen shares have a SELL rating. They show below average growth, are riskily financed, and are bad value. We recommend selling Qiagen shares.


Latest Obermatt Ranks


Country Netherlands
Industry Life Sciences Tools & Services
Index TecDAX, NASDAQ
Size class Large

March 22, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock






 

Research History: Qiagen

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
44
25
14
13
STOCK GROWTH RANKS
13
32
26
37
STOCK SAFETY RANKS
50
63
35
20
COMBINED STOCK RANKS
24
36
4
6

Last update of Combined Rank: 22-Mar-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Qiagen in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 22-Mar-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Qiagen; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
12
22
26
24
PROFIT GROWTH
16
26
57
74
STOCK RETURNS
64
51
34
30
CONSOLIDATED RANK: GROWTH
13
32
26
37

Financial reporting date of Growth Rank: 31-Dec-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Qiagen.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
22
47
30
32
REFINANCING
35
38
LIQUIDITY
75
63
35
37
CONSOLIDATED RANK: SAFETY
50
63
35
20

Financial reporting date of Safety Rank: 31-Dec-2017. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Qiagen and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Qiagen from March 22, 2018.